TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04708470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
Study: NCT06436482

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
Study: NCT05358951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-YA with Coaching
Description: Online instruction on behavioral changes to improve sleep with 2 additional individually coached session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEP-YA without Coaching
Description: Online instruction on behavioral changes to improve sleep without additional individually coached session
Study: NCT06319508

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
Study: NCT04708470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
Study: NCT04597671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is used as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab is used as standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose PCI
Description: PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
Study: NCT04911491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMST
Description: Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Repeated inhalations against a low resistance will be performed using a handheld device.
Study: NCT06275308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation manipulation
Description: Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
Study: NCT05636618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-α-NET
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-α-NET
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
Study: NCT05259839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etentamig
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etentamig
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etentamig
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etentamig
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral; Tablet or IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral; Tablet or IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral; Tablet or IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral; Tablet or IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Injection (SC)
Study: NCT05063565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere Y-90 glass microsphere therapy
Description: TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi) immunotherapy
Description: 1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab immunotherapy
Description: 300 mg, single administration
Study: NCT05348577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capivasertib
Description: 320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Study: NCT05049707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate
Description: 15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 cc normal saline delivered in equivalent rates as the treatment group
Study: NCT05447195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
Study: NCT02533232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 200mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Minocycline 200mg per day
Study: NCT05094011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aadipose-Derived Mesenchymal Stem Cells
Description: Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
Study: NCT06530732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
Study: NCT04256148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via intravenous (IV) infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sterile liquid diluent) administered via IV infusion
Study: NCT06550401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREAST-Q Physical Well-Being
Description: This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
Study: NCT05554393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06550401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QuickDASH
Description: QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
Study: NCT05554393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study: NCT04766164

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Data will be obtained via self-report from participants via a one-time Qualtrics survey.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Data will be obtained via self-report from participants via a one-time Qualtrics survey.
Study: NCT05554393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05060055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implant placement
Description: Immediate dental implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implant placement
Description: Immediate dental implant placement
Study: NCT06251336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UroialTM Plus
Description: Nutraceutical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet
Study: NCT05608291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered by IV infusion Q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered by IV infusion Q 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered by IV infusion Q 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
Study: NCT06022081

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung ultrasound to detect pneumothorax.
Description: Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
Study: NCT05686642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 Drug:high dose
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 Drug:low dose
Description: Administered by intravenous infusion.
Study: NCT05078866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopy with biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopy with biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopy with biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies